Literature DB >> 28612115

Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study.

Ekaterina Petrova1, Felix Rückert2, Sebastian Zach2, YinFeng Shen1,3, Jürgen Weitz4, Robert Grützmann4,5, Uwe A Wittel6, Frank Makowiec6, Ulrich T Hopt6, Peter Bronsert7, Florian Kühn8, Bettina M Rau8, Roman E Izrailov9, Igor E Khatkov9, Hryhoriy Lapshyn1, Louisa Bolm1, Dirk Bausch1, Tobias Keck10, Ulrich F Wellner1, Gabriel Seifert6.   

Abstract

PURPOSE: Pancreatoduodenectomy is the most common operative procedure performed for distal bile duct carcinoma. Data on outcome after surgery for this rare malignancy is scarce, especially from western countries. The purpose of this study is to explore the prognostic factors and outcome after pancreatoduodenectomy for distal bile duct carcinoma.
METHODS: Patients receiving pancreatoduodenectomy for distal bile duct carcinoma were identified from institutional databases of five German and one Russian academic centers for pancreatic surgery. Univariable and multivariable general linear model, Kaplan-Meier method, and Cox regression were used to identify prognostic factors for postoperative mortality and overall survival.
RESULTS: N = 228 patients operated from 1994 to 2015 were included. Reoperation (OR 5.38, 95%CI 1.51-19.22, p = 0.010), grade B/C postpancreatectomy hemorrhage (OR 3.73, 95%CI 1.13-12.35, p = 0.031), grade B/C postoperative pancreatic fistula (OR 4.29, 95%CI 1.25-14.72, p = 0.038), and advanced age (OR 4.00, 95%CI 1.12-14.03, p = 0.033) were independent risk factors for in-hospital mortality in multivariable analysis. Median survival was 29 months, 5-year survival 27%. Positive resection margin (HR 2.07, 95%CI 1.29-3.33, p = 0.003), high tumor grade (HR 1.71, 95%CI 1.13-2.58, p = 0.010), lymph node (HR 1.68, 95%CI 1.13-2.51, p = 0.011), and distant metastases (HR 2.70, 95%CI 1.21-5.58, p = 0.014), as well as severe non-fatal postoperative complications (HR 1.64, 95%CI 1.04-2.58, p = 0.033) were independent negative prognostic factors for survival in multivariable analysis.
CONCLUSION: Distant metastases and positive resection margin are the strongest negative prognostic factors for survival after pancreatoduodenectomy for distal bile duct carcinoma; thus, surgery with curative intent is only warranted in patients with local disease, where R0 resection is feasible.

Entities:  

Keywords:  Distal bile duct carcinoma; Distal cholangiocarcinoma; Pancreatic surgery; Pancreatoduodenectomy; Periampullary carcinoma

Mesh:

Year:  2017        PMID: 28612115     DOI: 10.1007/s00423-017-1590-9

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  31 in total

1.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

2.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

3.  Prognostic impact of lymph node metastasis in distal cholangiocarcinoma.

Authors:  M Kiriyama; T Ebata; T Aoba; Y Kaneoka; T Arai; Y Shimizu; M Nagino
Journal:  Br J Surg       Date:  2015-01-22       Impact factor: 6.939

4.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

5.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

6.  Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

Authors:  Matthew H Kulke; Margaret A Tempero; Donna Niedzwiecki; Donna R Hollis; Hedy L Kindler; Michael Cusnir; Peter C Enzinger; Stefan M Gorsch; Richard M Goldberg; Robert J Mayer
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

7.  Prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lymphovascular invasion.

Authors:  Hee Joon Kim; Choong Young Kim; Young Hoe Hur; Yang Seok Koh; Jung Chul Kim; Hyun Jong Kim; Chol Kyoon Cho
Journal:  Surg Today       Date:  2014-02-18       Impact factor: 2.549

Review 8.  The rise of multiple imputation: a review of the reporting and implementation of the method in medical research.

Authors:  Panteha Hayati Rezvan; Katherine J Lee; Julie A Simpson
Journal:  BMC Med Res Methodol       Date:  2015-04-07       Impact factor: 4.615

9.  Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma.

Authors:  Marius Distler; Felix Rückert; Maximilian Hunger; Stephan Kersting; Christian Pilarsky; Hans-Detlev Saeger; Robert Grützmann
Journal:  BMC Surg       Date:  2013-04-22       Impact factor: 2.102

Review 10.  Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity.

Authors:  Rosa B Schmuck; Cynthia V de Carvalho-Fischer; Christopher Neumann; Johann Pratschke; Marcus Bahra
Journal:  Cancer Med       Date:  2015-12-09       Impact factor: 4.452

View more
  8 in total

1.  Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies.

Authors:  Stefan Buettner; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Matthew Weiss; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Bas Groot Koerkamp; Shishir K Maithel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-09-14       Impact factor: 3.452

2.  Surgical outcomes and prognostic factors of distal common bile duct adenocarcinoma: chronological analysis in a single high-volume institutional experience.

Authors:  Ji Hye Jung; So Jeong Yoon; Ok Joo Lee; Sang Hyun Shin; In Woong Han; Jin Seok Heo
Journal:  BMC Surg       Date:  2022-07-04       Impact factor: 2.030

3.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

4.  The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer.

Authors:  Weiyao Li; Javier Martinez-Useros; Nuria Garcia-Carbonero; Maria J Fernandez-Aceñero; Luis Ortega-Medina; Sandra Garcia-Botella; Elia Perez-Aguirre; Luis Diez-Valladares; Jesus Garcia-Foncillas
Journal:  J Clin Med       Date:  2019-08-22       Impact factor: 4.241

5.  Serum carcinoembryonic antigen and carbohydrate antigen 19-9 as preoperative diagnostic biomarkers of extrahepatic bile duct cancer.

Authors:  Hyeong Seok Kim; Youngmin Han; Jae Seung Kang; Yoon Hyung Kang; Mirang Lee; Hee Ju Sohn; Hongbeom Kim; Wooil Kwon; Jin-Young Jang
Journal:  BJS Open       Date:  2021-11-09

6.  Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy.

Authors:  Chaobin He; Yize Mao; Jun Wang; Fangting Duan; Xiaojun Lin; Shengping Li
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

7.  Relevant prognostic factors influencing outcome of patients after surgical resection of distal cholangiocarcinoma.

Authors:  Oliver Beetz; Michael Klein; Harald Schrem; Jill Gwiasda; Florian W R Vondran; Felix Oldhafer; Sebastian Cammann; Jürgen Klempnauer; Karl J Oldhafer; Moritz Kleine
Journal:  BMC Surg       Date:  2018-08-13       Impact factor: 2.102

8.  The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis.

Authors:  Yoichi Miyata; Ryota Kogure; Akiko Nakazawa; Rihito Nagata; Tetsuya Mitsui; Riki Ninomiya; Masahiko Komagome; Akira Maki; Nobuaki Kawarabayashi; Yoshifumi Beck
Journal:  J Clin Med       Date:  2021-03-01       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.